Surgical Innovations (SUN) AI Stock Analysis

• Market Cap: £6.53M
• Dividend Yield: N/A
• Average Volume (3M): 248.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: -0.57%
• EPS Growth: -320.00%
• Country: UK
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 932,816,160
• 10 Day Avg. Volume: 60,886
• 30 Day Avg. Volume: 248,094
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £0.50
• Price Target Upside: -23.08% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: 0.50p ▼(-23.08% Downside)

Surgical Innovations' overall stock score is driven by positive technical analysis and supportive corporate events. However, financial performance and valuation issues, such as negative profitability and unattractive valuation metrics, weigh down the score.

Surgical Innovations Business Overview & Revenue Model

Company Description

Surgical Innovations Group plc, together with its subsidiaries, designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The company's SI Brand segment researches, develops, manufactures, and distributes SI branded minimally invasive devices. This segment also offers YelloPort Elite and YelloPort +plus laparoscopic port access systems; LogiRange resposable laparoscopic instrument systems; FastClamp laparoscopic clamping systems; and QuickRange single use laparoscopic instrumentation. Its OEM segment researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through own label or co-branding. This segment also provides design and development solutions for producing a final device; and researches, develops, manufactures, and sells minimally invasive technology products for precision engineering applications. The company's Distribution segment distributes medical products through Elemental Healthcare Ltd. It also designs and manufactures autologous blood products. It sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was incorporated in 1988 and is based in Leeds, the United Kingdom.

How the Company Makes Money

Surgical Innovations generates revenue through the sale of its surgical instruments and devices to hospitals, surgical centers, and healthcare providers. The company’s core revenue streams include direct sales of its minimally invasive surgical tools and equipment, as well as recurring revenue from maintenance contracts and servicing agreements for its devices. Additionally, SUN may engage in strategic partnerships with other medical technology firms or healthcare organizations to co-develop products, which can provide further revenue opportunities through joint ventures or licensing agreements. The company also invests in research and development to create innovative products that meet the evolving needs of surgeons and patients, thus ensuring sustained market demand and profitability.

Surgical Innovations Financial Statement Overview

Summary

Surgical Innovations is facing financial challenges with declining revenue, negative profitability, and cash flow issues. Leverage is manageable, but operational inefficiencies and lack of profitability are concerning.

Income Statement

The company's income statement shows declining revenue and profitability over the past year. Gross Profit Margin remained stable at around 28.8%, but Net Profit Margin deteriorated from -4.2% to -16.3%. Revenue decreased by 0.6%, indicating challenges in maintaining growth. EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet is relatively stable but shows some weaknesses. The Debt-to-Equity Ratio improved to 0.15, indicating manageable leverage levels. However, the Equity Ratio decreased slightly to 69.8%. Return on Equity (ROE) is negative due to net losses, highlighting profitability issues.

Cash Flow

Cash flow analysis reveals challenges in cash generation. Operating Cash Flow turned negative, and Free Cash Flow decreased further into negative territory. The Operating Cash Flow to Net Income Ratio is weak due to negative earnings, and Free Cash Flow to Net Income is negative, indicating cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.95M	12.01M	11.34M	9.13M	6.33M
Gross Profit	3.44M	3.45M	3.92M	3.13M	1.27M
EBITDA	-99.00K	161.00K	628.00K	247.00K	-2.20M
Net Income	-1.94M	-509.00K	264.00K	-456.00K	-3.28M
Balance Sheet
Total Assets	12.24M	14.32M	15.60M	15.72M	16.34M
Cash, Cash Equivalents and Short-Term Investments	195.00K	1.21M	2.20M	3.64M	5.28M
Total Debt	1.24M	1.66M	2.16M	2.79M	3.27M
Total Liabilities	3.70M	3.84M	4.63M	5.05M	5.25M
Stockholders Equity	8.54M	10.48M	10.96M	10.66M	11.09M
Cash Flow
Free Cash Flow	-409.00K	-288.00K	-592.00K	-1.09M	887.00K
Operating Cash Flow	-74.00K	400.00K	486.00K	-433.00K	1.04M
Investing Cash Flow	-335.00K	-688.00K	-1.08M	-657.00K	-155.00K
Financing Cash Flow	-626.00K	-672.00K	-935.00K	-532.00K	3.15M

Surgical Innovations Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SUN, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.70, and above the 200-day MA of 0.62, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 0.29 is Positive, neither overbought nor oversold. The STOCH value of 54.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SUN.

Surgical Innovations Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUN	60 Neutral	£6.53M	―	-20.43%	―	-0.57%	-320.00%
RUA	55 Neutral	£6.98M	1,125.00	―	―	87.72%	―
TRX	49 Neutral	£15.67M	-28.21	-2.39%	―	-5.33%	60.20%
CREO	44 Neutral	£50.01M	-2.03	-67.69%	―	―	―
IHC	40 Underperform	£19.28M	-1.20	-89.97%	―	1.65%	-102.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Surgical Innovations Corporate Events

Surgical Innovations to Announce Interim Results with Investor Briefing

Surgical Innovations Group plc announced the release of its interim results for the first half of 2025, scheduled for 29 September 2025. The company will hold a live presentation for investors, led by CEO David Marsh and CFO Brent Greetham, to discuss these results. This event is accessible to all current and potential shareholders, highlighting the company’s commitment to transparency and engagement with its stakeholders.

The most recent analyst rating on (GB:SUN) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Surgical Innovations stock, see the GB:SUN Stock Forecast page.

Surgical Innovations Group Announces AGM Results with Strong Shareholder Support

Surgical Innovations Group plc announced that all resolutions at their Annual General Meeting were passed, except for two that were withdrawn. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives in the medical technology sector, particularly in minimally invasive surgery.

Surgical Innovations Withdraws AGM Resolutions Amid Shareholder Feedback

Surgical Innovations Group plc has withdrawn Resolutions 9 and 10 from its upcoming AGM agenda following feedback from significant shareholders. These resolutions pertained to the disapplication of pre-emption rights for equity securities, which the Board initially deemed beneficial for the company. Despite the withdrawal, the AGM will proceed as planned, and the company does not foresee needing to raise new funds through non pre-emptive share issues before the 2026 AGM. This decision reflects the company’s responsiveness to shareholder concerns while maintaining its strategic and operational stability.